|Articles|March 31, 2023

Some Young People Have Long COVID Symptoms Despite Never Contracting COVID-19

Author(s)Nina Cosdon

These findings suggest the World Health Organization's definition of post-COVID-19 condition (long COVID) may be too broad.

As COVID-19 prevention and treatment therapies become more advanced, the treatment focus has shifted to post-COVID-19 condition (PCC), or “long COVID.”

Mysteriously, long COVID is not limited to individuals at high risk of severe COVID-19 infection, such as persons who are older or immunocompromised. Many young people who only had mild acute infection go on to develop long COVID, yet the commonality and baseline risk factors of PCC remain unknown.

A new original investigation, published in JAMA Network Open, sought to determine the prevalence and associated risk factors of long COVID in young people after acute infection.

The prospective cohort study included nonhospitalized persons from 2 counties in southeast Norway, aged between 12-25 years. The individuals underwent reverse transcription-polymerase chain reaction (RT-PCR) testing to confirm their COVID-19 infection.

At the early stages of recovery and at a 6-month follow-up, participants underwent pulmonary, cardiac, and cognitive functional testing, immunological and organ injury biomarker analyses, and completed questionnaires. The investigators performed association analyses of 78 potential risk factors.

The team used the World Health Organization (WHO) case definition of long COVID, which broadly classifies any symptom occurring in the aftermath of acute COVID-19 as PCC. The WHO definition does not require symptom persistence since acute infection, nor significant disability.

A total of 382 COVID-19−positive and 85 COVID-19−negative young people were enrolled and participated in the entirety of the study. The cohorts were 38.1% male and 20.0% non-European ethnicity. After 6 months, the point prevalence of PCC according to the WHO definition was 48.5% in the COVID-19−positive group and 47.1% in the control cohort.

Interestingly, these results suggest that COVID-19 positivity was not associated with the development of long COVID. While the main risk factor for PCC was symptom severity at baseline, low physical activity and loneliness were also associated. Additionally, symptom severity was associated with personality traits. Biological markers had no correlation with the development of long COVID.

“The persistent symptoms and disability that characterize PCC are associated with factors other than SARS-CoV-2 infection, including psychosocial factors,” the study authors concluded. “This finding raises questions about the utility of the World Health Organization case definition and has implications for the planning of health care services as well as for further research on PCC.”


Related to this article

Measles Update: October 30, 2026
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.
Measles Update: October 23, 2026
The latest CDC numbers show a 4.0% increase in measles cases from week-to-week, bringing the 2026 US total to 4588 confirmed cases. Ninety-six percent of cases are outbreak-associated.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.